| Autor: |
Esther Kissling, Francisco Pozo, Silke Buda, Ana-Maria Vilcu, Caterina Rizzo, Alin Gherasim, Judit Krisztina Horváth, Mia Brytting, Lisa Domegan, Adam Meijer, Iwona Paradowska-Stankiewicz, Ausenda Machado, Vesna Višekruna Vučina, Mihaela Lazar, Kari Johansen, Ralf Dürrwald, Sylvie van der Werf, Antonino Bella, Amparo Larrauri, Annamária Ferenczi, Katherina Zakikhany, Joan O'Donnell, Frederika Dijkstra, Joanna Bogusz, Raquel Guiomar, Sanja Kurečić Filipović, Daniela Pitigoi, Pasi Penttinen, Marta Valenciano |
| Jazyk: |
angličtina |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Vaccine: X, Vol 3, Iss , Pp - (2019) |
| Druh dokumentu: |
article |
| ISSN: |
2590-1362 |
| DOI: |
10.1016/j.jvacx.2019.100042 |
| Popis: |
Introduction: Influenza A(H3N2) viruses predominated in Europe in 2016–17. In 2017–18 A(H3N2) and A(H1N1)pdm09 viruses co-circulated. The A(H3N2) vaccine component was the same in both seasons; while the A(H1N1)pdm09 component changed in 2017–18. In both seasons, vaccine seed A(H3N2) viruses developed adaptations/alterations during propagation in eggs, impacting antigenicity. Methods: We used the test-negative design in a multicentre primary care case-control study in 12 European countries to measure 2016–17 and 2017–18 influenza vaccine effectiveness (VE) against laboratory-confirmed influenza A(H1N1)pdm09 and A(H3N2) overall and by age group. Results: During the 2017–18 season, the overall VE against influenza A(H1N1)pdm09 was 59% (95% CI: 47–69). Among those aged 0–14, 15–64 and ≥65 years, VE against A(H1N1)pdm09 was 64% (95% CI: 37–79), 50% (95% CI: 28–66) and 66% (95% CI: 42–80), respectively. Overall VE against influenza A(H3N2) was 28% (95% CI: 17–38) in 2016–17 and 13% (95% CI: −15 to 34) in 2017–18. Among 0–14-year-olds VE against A(H3N2) was 28% (95%CI: −10 to 53) and 29% (95% CI: −87 to 73), among 15–64-year-olds 34% (95% CI: 18–46) and 33% (95% CI: −3 to 56) and among those aged ≥65 years 15% (95% CI: −10 to 34) and −9% (95% CI: −74 to 32) in 2016–17 and 2017–18, respectively. Conclusions: Our study suggests the new A(H1N1)pdm09 vaccine component conferred good protection against circulating strains, while VE against A(H3N2) was |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
